Staging tells your doctor how deeply the tumour has grown into the bladder wall, whether it has reached lymph nodes in the pelvis, and whether it has spread to distant organs. For bladder cancer the system used at every major centre in Delhi, Gurgaon and Noida is the American Joint Committee on Cancer Tumour-Node-Metastasis classification, 8th edition (AJCC TNM 8e) [^1][^2]. The staging creates a divide that shapes every treatment decision: tumours that have not invaded the muscularis propria (stages Ta, Tis, T1) are grouped as non-muscle-invasive bladder cancer (NMIBC), while those that have entered or passed through the muscle layer (T2 and above) are grouped as muscle-invasive bladder cancer (MIBC). About 75 percent of patients are diagnosed with NMIBC, and the remaining 25 percent present with MIBC or metastatic disease at first diagnosis [^3][^4].
The distinction matters because NMIBC is usually managed with endoscopic resection and intravesical therapy, while MIBC typically calls for radical cystectomy with or without chemotherapy. Clinical staging is done before surgery using cystoscopy, imaging and biopsy results. Pathological staging is assigned after the specimen is examined under the microscope and is more accurate because the pathologist can assess exact muscle invasion depth, margin status, lymphovascular invasion and lymph node involvement [^2][^5].
Understanding the stage helps patients and families across the National Capital Region ask the right questions at the tumour board and plan realistic timelines for treatment.
What Bladder Cancer Staging Actually Means
Staging tells your doctor how deeply the tumour has grown into the bladder wall, whether it has reached lymph nodes in the pelvis, and whether it has spread to distant organs. For bladder cancer the staging system used at leading cancer centres in the region Hospital and other centres across Delhi, Gurgaon and Noida is the American Joint Committee on Cancer Tumour-Node-Metastasis classification, 8th edition (AJCC TNM 8e) [^1][^2]. It assigns three descriptors. T describes how far the primary tumour has penetrated through the layered bladder wall: the urothelium (inner lining), the lamina propria (a thin connective tissue layer beneath it), the muscularis propria (the thick muscle coat, also called the detrusor), and the perivesical fat beyond the muscle. N records whether cancer cells have reached regional pelvic lymph nodes. M records whether there is spread to a distant organ such as the lungs, liver or bone.
The staging system creates a fundamental divide. Tumours that have not invaded the muscularis propria (Ta, Tis, T1) are grouped as non-muscle-invasive bladder cancer, abbreviated NMIBC. Tumours that have entered or passed through the muscle layer (T2 and above) are grouped as muscle-invasive bladder cancer, or MIBC. Roughly 75 percent of patients are diagnosed with NMIBC and the remaining 25 percent present with MIBC or metastatic disease at first diagnosis [^3][^4]. The distinction matters because NMIBC is usually managed with endoscopic resection and intravesical therapy, while MIBC typically calls for radical cystectomy with or without chemotherapy.
Clinical staging is done before surgery using cystoscopy, imaging and biopsy results. Pathological staging is assigned after the specimen is examined under the microscope and is more accurate because the pathologist can assess exact muscle invasion depth, margin status, lymphovascular invasion and lymph node involvement [^2][^5]. Within NMIBC, oncologists further stratify tumours into low, intermediate and high risk groups using scoring tools such as the European Organisation for Research and Treatment of Cancer (EORTC) risk tables.
Why Bladder Cancer Uses TNM and the NMIBC Versus MIBC Divide
The TNM system provides the anatomical foundation for bladder cancer staging. T describes the depth of invasion through the layered bladder wall, N the regional pelvic lymph node status, and M the presence of distant metastases. This classification allows clinicians to communicate with precision and compare outcomes between institutions [^1][^2].
What makes bladder cancer staging distinctive is the biological threshold at the muscularis propria. A tumour that sits above the detrusor muscle, even if it has grown through the lamina propria, behaves in a fundamentally different way from one that has reached or passed through the muscle coat. NMIBC recurs frequently inside the bladder but rarely kills; MIBC carries a meaningful risk of nodal and distant spread. This single boundary drives the entire treatment algorithm: endoscopic management and intravesical instillations on the NMIBC side, radical surgery or trimodal therapy on the MIBC side [^3][^5].
Within NMIBC, the EORTC risk tables combine stage, grade, tumour size, number of tumours, presence of carcinoma in situ and prior recurrence history to separate patients into low, intermediate and high risk groups. The risk group determines whether the patient needs a single post-TURBT chemotherapy instillation, a course of intravesical BCG, or early discussion of cystectomy [^4][^6]. Within MIBC, the decision between radical cystectomy and bladder-sparing trimodal therapy depends on tumour location, multifocality, hydronephrosis and patient fitness.
Subtypes of Bladder Cancer Under WHO 2022
The bladder gives rise to several tumour types. The World Health Organization 5th edition classification of urinary tumours (2022) updated the nomenclature, replacing the older term “variants” with “subtypes” to reflect meaningful differences in biology and behaviour [^7][^8].
Urothelial carcinoma, conventional type, is the dominant histology in India and worldwide, accounting for roughly 90 percent of bladder cancers. It originates from the transitional epithelium that lines the bladder and can be papillary (growing on a stalk toward the lumen) or flat, graded as low grade or high grade. Low-grade papillary tumours recur frequently but rarely invade muscle. High-grade tumours carry a higher risk of muscle invasion and metastasis [^3][^7].
Urothelial carcinoma with divergent differentiation is found in 15 to 25 percent of invasive cases. The pathologist identifies areas that look like squamous epithelium, glandular tissue or other lineages mixed in with the urothelial component. WHO 2022 recognises multiple subtypes: micropapillary, plasmacytoid, sarcomatoid, nested, microcystic, lymphoepithelioma-like and giant cell. All subtypes of invasive urothelial carcinoma are high grade by definition, even those with a bland microscopic appearance such as nested and microcystic. Micropapillary and plasmacytoid subtypes are particularly aggressive and often prompt earlier consideration of radical cystectomy [^7][^8][^9].
Pure squamous cell carcinoma represents roughly five to eight percent of bladder cancers in India and is associated with chronic irritation from long-standing catheterisation, bladder stones or recurrent urinary infections [^3][^10]. Adenocarcinoma of the bladder is rare and includes urachal adenocarcinoma arising at the dome from a urachal remnant. Small-cell or neuroendocrine carcinoma of the bladder is rare, highly aggressive and managed with platinum-etoposide chemotherapy similar to small-cell lung cancer protocols [^3][^5].
For staging purposes, all histologic types of bladder cancer use the same AJCC TNM 8e system, but prognosis and treatment selection differ by subtype. Pure squamous cell and adenocarcinoma are generally less responsive to cisplatin-based chemotherapy than conventional urothelial carcinoma [^5][^10].
Urothelial Carcinoma: The Most Common Bladder Cancer
Conventional urothelial carcinoma accounts for roughly 90 percent of all bladder cancers diagnosed in India and across the world [^3][^7]. It arises from the transitional epithelium (urothelium) that lines the inner surface of the bladder. The urothelium is only a few cell layers thick, but it is uniquely exposed to carcinogens: the kidneys filter toxic metabolites from the bloodstream, concentrate them in urine, and that urine sits in contact with the bladder lining for hours at a stretch. This prolonged exposure explains why tobacco smoking and occupational chemical exposure are the two strongest risk factors for bladder cancer.
Under the microscope, urothelial carcinoma is graded as low grade or high grade. Low-grade tumours tend to form papillary fronds that project into the bladder lumen on a fibrovascular stalk. They recur frequently, sometimes many times over a patient’s lifetime, but they rarely invade the muscle layer or metastasise. High-grade urothelial carcinoma shows more disordered cell architecture, frequent mitoses and nuclear atypia. It may grow as a papillary mass, a sessile (broad-based) tumour, or a flat lesion such as carcinoma in situ. High-grade disease carries a substantially higher risk of muscle invasion, lymph node involvement and distant spread [^3][^7][^8].
The practical implication for patients is that the grade on the TURBT pathology report, combined with the T category, determines the risk group and therefore the intensity of intravesical treatment and surveillance. A patient with a single small low-grade Ta tumour faces a very different trajectory from a patient with multifocal high-grade T1 disease with concomitant CIS.
Squamous Cell, Adenocarcinoma and Neuroendocrine Bladder Cancer Subtypes
Pure squamous cell carcinoma of the bladder represents roughly five to eight percent of cases in India. It is linked to chronic bladder irritation: long-standing indwelling catheters, untreated bladder stones, and recurrent urinary tract infections create an environment of chronic inflammation that promotes squamous metaplasia over time. In regions where urinary schistosomiasis is endemic the proportion is higher, though schistosomiasis is uncommon across most of India. Treatment centres on radical cystectomy; these tumours respond poorly to cisplatin-based chemotherapy compared with conventional urothelial carcinoma [^3][^10].
Adenocarcinoma of the bladder is rare. The urachal subtype arises at the dome from a urachal remnant and tends to present with mucus in the urine or a midline abdominal mass. Non-urachal bladder adenocarcinoma may occur in the setting of chronic irritation or bladder exstrophy. Surgery is the primary treatment, and when systemic therapy is needed clinicians borrow from colorectal or gastric protocols because urothelial-directed regimens have limited activity against glandular histology [^3][^10].
Small-cell (neuroendocrine) carcinoma of the bladder is the rarest of the major subtypes and the most aggressive. It grows rapidly, metastasises early, and is managed with platinum-etoposide chemotherapy, radiation and sometimes surgery, following treatment principles developed for small-cell lung cancer. Mixed tumours containing both urothelial and neuroendocrine components are staged using the AJCC TNM 8e bladder system and treated according to the small-cell component [^3][^5].
Carcinoma In Situ and the Risk of Bladder Cancer Progression
Carcinoma in situ (CIS, staged as Tis) is a flat, high-grade urothelial lesion that sits flush with the bladder surface and may be invisible on standard white-light cystoscopy. Unlike papillary tumours that project into the bladder lumen, CIS does not form a visible mass, yet it is biologically aggressive. Left untreated, CIS progresses to muscle-invasive disease in a substantial proportion of patients over five to ten years [^3][^6].
CIS may occur alone (primary CIS), alongside a papillary tumour (concomitant CIS), or recur after treatment (recurrent CIS). Its presence markedly increases the risk of both recurrence and progression. When a pathologist reports CIS in random biopsies taken away from the main tumour, it signals that the entire urothelium is at risk and that a single TURBT will not control the field.
The standard treatment for CIS is a six-week induction course of intravesical BCG immunotherapy, followed by maintenance BCG for at least one year. Response is assessed by cystoscopy and urine cytology at three months. Patients who achieve a complete response continue maintenance. Those whose CIS persists or recurs after adequate BCG exposure are classified as BCG-unresponsive and should be considered for radical cystectomy or, if they decline or are unfit, newer bladder-sparing agents such as pembrolizumab (KEYNOTE-057) or nadofaragene firadenovec gene therapy [^5][^6][^19][^26].
The T Descriptor in Bladder Cancer: Ta Through T4
The T category describes how far the primary bladder tumour has penetrated through the layered wall of the bladder. Each layer represents a biological threshold with implications for treatment and outcome [^1][^2][^18].
Ta is a papillary tumour confined to the urothelium that grows into the bladder lumen on a stalk but has not invaded the lamina propria beneath it. Ta tumours are non-invasive. The majority are low grade. They recur frequently but rarely progress to muscle invasion on their own. Tis (carcinoma in situ) is a flat, high-grade lesion within the urothelium that does not form a papillary mass. Despite its flat appearance, CIS is biologically aggressive and carries a meaningful risk of progressing to MIBC if untreated [^1][^3][^6].
T1 means the tumour has grown through the urothelium and into the lamina propria but has not reached the muscularis propria. T1 high-grade tumours are the most challenging category in NMIBC management because the risk of under-staging at initial TURBT is high, and progression to muscle invasion occurs in a substantial minority even with intravesical therapy. Re-staging TURBT is considered mandatory for T1 high-grade lesions [^1][^3][^5][^6].
T2 means the tumour has invaded the muscularis propria (detrusor muscle). This is the threshold that separates NMIBC from MIBC and triggers consideration of radical cystectomy or trimodal therapy. T2a denotes invasion limited to the inner (superficial) half of the muscle. T2b denotes invasion extending into the outer (deep) half. The distinction can only be made reliably on the pathological specimen after cystectomy, not on a TURBT chip alone [^1][^2][^5][^18].
T3 means the tumour has grown through the full thickness of the muscularis propria and into the perivesical fat. T3a denotes microscopic extravesical extension detected only under the microscope. T3b denotes macroscopic extravesical extension visible to the surgeon or on imaging. T3 disease substantially reduces the probability of cure with surgery alone, and neoadjuvant chemotherapy carries a stronger rationale at this stage [^1][^2][^5].
T4 means the tumour has invaded adjacent organs or structures. T4a indicates invasion of the prostate stroma (in men), the uterus or the vagina (in women). T4b indicates invasion of the pelvic sidewall or the abdominal wall. T4b disease is generally considered unresectable [^1][^2][^5].
The N and M Descriptors in Urothelial Carcinoma
N describes whether cancer cells have reached regional pelvic lymph nodes. N0 means no cancer in regional nodes. N1 means a single lymph node in the true pelvis (perivesical, obturator, internal iliac or external iliac region) contains cancer. N2 means two or more lymph nodes in the true pelvis are involved. N3 means cancer has reached the common iliac lymph nodes [^1][^2].
Lymph node involvement is one of the strongest prognostic factors after radical cystectomy. The more nodes involved and the higher the nodal station, the worse the outlook. Extended pelvic lymph node dissection at the time of cystectomy provides both staging accuracy and a potential therapeutic benefit, particularly when a higher node count is achieved [^5].
M describes distant metastasis. M0 means no distant metastasis detected on imaging. M1a means cancer has spread to lymph nodes beyond the common iliac region (non-regional nodes). M1b means cancer has spread to distant organs such as the lungs, liver, bone or peritoneum [^1][^2]. The M category determines whether treatment is given with curative or palliative intent.
Stage 0 Bladder Cancer: Ta and Tis Non-Invasive Disease
Stage 0 bladder cancer comes in two forms. Stage 0a (Ta, N0, M0) is non-invasive papillary carcinoma: a tumour that grows on a stalk into the bladder lumen but has not penetrated the lamina propria. Stage 0is (Tis, N0, M0) is flat carcinoma in situ confined to the urothelium [^1][^3][^18].
Stage 0a is managed by TURBT followed by risk-stratified surveillance. For a suspected low-risk Ta tumour, a single dose of intravesical mitomycin C (40 mg) or gemcitabine (2 g) instilled within 24 hours of resection reduces the one-year recurrence rate by roughly 35 to 40 percent [^3][^5][^6]. Patients with intermediate-risk Ta tumours may receive a course of intravesical BCG or additional chemotherapy instillations. Surveillance cystoscopy begins at three months and continues at gradually lengthening intervals.
Stage 0is is treated with a six-week induction course of intravesical BCG immunotherapy, followed by maintenance BCG using the SWOG schedule (three weekly instillations at months 3, 6, 12, 18, 24, 30 and 36). Response is assessed by cystoscopy and cytology at three months. CIS that persists or recurs after adequate BCG is classified as BCG-unresponsive and requires either cystectomy or a bladder-sparing salvage agent [^3][^5][^6].
Stage I Bladder Cancer: T1 Lamina Propria Invasion
Stage I bladder cancer (T1, N0, M0) means the tumour has grown through the urothelium and into the lamina propria but has not reached the muscularis propria. It remains within the NMIBC category, but T1 high-grade disease is the most difficult management challenge in non-invasive bladder cancer because the risk of under-staging at initial TURBT is high [^1][^3][^5].
After the initial TURBT, a re-staging resection within two to six weeks is considered mandatory for all T1 high-grade tumours. Up to 40 percent of T1 tumours are upstaged to T2 on re-resection, which changes the treatment plan entirely. If re-staging confirms T1, the patient receives intravesical BCG induction and maintenance. The EORTC risk tables help quantify the probability of recurrence and progression based on grade, size, number of tumours, concomitant CIS and prior recurrence history [^3][^5][^6].
Patients who fail BCG (BCG-unresponsive T1 high-grade disease) face a decision between radical cystectomy and bladder-sparing options. Cystectomy offers the most definitive cancer control. For patients who decline surgery or are medically unfit, alternatives include pembrolizumab (KEYNOTE-057 trial, complete response rate approximately 41 percent), nadofaragene firadenovec gene therapy (Adstiladrin, complete response rate approximately 53 percent at three months), and sequential intravesical gemcitabine plus docetaxel (one-year high-grade recurrence-free survival of approximately 60 to 70 percent) [^5][^6][^19][^25][^26].
Stage II Bladder Cancer: Muscle-Invasive Disease
Stage II bladder cancer (T2a or T2b, N0, M0) means the tumour has invaded the muscularis propria (detrusor muscle) without lymph node involvement or distant spread. This is the stage at which management shifts from endoscopic bladder-sparing approaches to systemic and surgical treatment [^1][^5][^18].
The standard of care is neoadjuvant cisplatin-based chemotherapy, typically gemcitabine plus cisplatin or dose-dense MVAC, for three to four cycles followed by radical cystectomy with bilateral pelvic lymph node dissection. The ABC Meta-analysis Collaboration demonstrated a five percent absolute overall survival benefit at five years with neoadjuvant cisplatin-based chemotherapy. Patients who achieve a pathological complete response (pT0) at cystectomy have substantially better long-term outcomes [^5][^18][^28].
For selected patients who strongly prefer to keep their bladder, trimodal therapy (maximal TURBT followed by concurrent radiosensitising chemotherapy and external-beam radiation to the bladder) is an alternative with comparable survival in carefully chosen cases. Ideal candidates have a single T2 tumour, complete visible resection at TURBT, no CIS, no hydronephrosis, and adequate bladder capacity. Published long-term series from Massachusetts General Hospital and the BC2001 and BCON UK trials report five-year overall survival rates of 50 to 60 percent for selected patients [^5][^10][^30].
For patients who received neoadjuvant chemotherapy and have residual high-risk pathology at cystectomy, adjuvant nivolumab for up to one year is an option supported by the CheckMate 274 trial [^20][^21].
Stage III Bladder Cancer: Extravesical Extension and Node-Positive Disease
Stage III bladder cancer is divided into IIIA and IIIB. Stage IIIA includes T3a, T3b or T4a tumours with N0 M0, or T1 through T4a with a single positive pelvic lymph node (N1, M0). Stage IIIB includes T1 through T4a with multiple involved pelvic lymph nodes (N2 or N3, M0) [^1][^5][^18].
The treatment approach follows the same principle as Stage II, with an even stronger emphasis on neoadjuvant chemotherapy because the benefit of downstaging is greater when the initial tumour burden is higher. Radical cystectomy with extended lymph node dissection is performed after three to four cycles of cisplatin-based chemotherapy. The NIAGARA trial (phase III) tested neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab versus chemotherapy alone and showed a statistically significant improvement in event-free survival and overall survival, establishing a perioperative immunotherapy option for eligible patients [^5][^22][^29].
Adjuvant nivolumab after cystectomy showed a disease-free survival advantage in this population in CheckMate 274, particularly in patients with PD-L1 expression of one percent or more. Median disease-free survival was 21.9 months with nivolumab versus 11.0 months with placebo in the overall population, rising to 55.5 months versus 8.4 months in PD-L1-positive patients. Five-year follow-up confirmed durable benefit [^20][^21].
Stage IV Bladder Cancer: Fixed Tumours, Non-Regional Nodes and Distant Metastases
Stage IVA includes T4b (tumour fixed to the pelvic or abdominal wall) with any N and M0, or any T with any N and M1a (non-regional lymph node spread). Stage IVB is any T, any N, M1b (distant organ metastasis to lung, liver, bone or peritoneum) [^1][^2][^18].
Systemic therapy is the primary modality. The current preferred first-line regimen for locally advanced unresectable or metastatic urothelial carcinoma is enfortumab vedotin combined with pembrolizumab (EV+P), based on the phase III EV-302/KEYNOTE-A39 trial. In that study, 886 patients were randomised; median overall survival was 31.5 months with EV+P versus 16.1 months with platinum-based chemotherapy (hazard ratio 0.47). Median progression-free survival was 12.5 months versus 6.3 months [^22][^23][^24].
For patients who cannot access enfortumab vedotin, cisplatin-eligible patients may receive gemcitabine plus cisplatin followed by maintenance avelumab for those who have not progressed, based on the JAVELIN Bladder 100 trial (overall survival 21.4 months versus 14.3 months with supportive care alone). Cisplatin-ineligible patients receive gemcitabine plus carboplatin followed by the same avelumab maintenance [^5][^23][^31].
Palliative radiation may address symptomatic bone or brain metastases. Clinical trial enrolment should be discussed at every progression point [^5][^22].
EORTC Risk Tables for Non-Muscle-Invasive Bladder Cancer
Within NMIBC, not all tumours carry the same threat. The European Organisation for Research and Treatment of Cancer developed risk tables that predict both recurrence and progression for individual patients based on six clinical and pathological factors: the number of tumours, tumour size, prior recurrence rate, T category (Ta versus T1), concurrent CIS, and WHO grade. Each factor is assigned a weighted score, and the totals place the patient into a low, intermediate or high risk group [^4][^6].
A patient in the low-risk group (for example, a single small low-grade Ta tumour with no prior recurrences) has a one-year recurrence probability of roughly 15 percent and a five-year progression probability below two percent. A patient in the high-risk group (for example, multifocal high-grade T1 with concomitant CIS) may face a one-year recurrence probability above 60 percent and a five-year progression probability exceeding 40 percent [^4][^6].
The risk group drives treatment intensity. Low-risk patients receive a single post-TURBT intravesical instillation and enter surveillance. Intermediate-risk patients receive either a chemotherapy instillation schedule or BCG induction. High-risk patients receive BCG induction plus maintenance for one to three years. Some guidelines recommend discussing early cystectomy with the highest-risk patients, particularly those with multifocal T1 high-grade disease, extensive CIS, prostatic urethral involvement and lymphovascular invasion on the TURBT specimen [^5][^6].
Symptoms of Early Bladder Cancer in Delhi NCR
The symptom that sends most patients toward a diagnosis is blood in the urine. Painless visible haematuria is the single most common presentation and the most telling signal. The urine may appear pink, rust-coloured or frankly red. It tends to come and go: a patient may notice blood for two or three days, then the urine clears for weeks, creating a false sense that the problem has resolved. Any episode of visible blood in the urine in an adult over forty should be investigated with at least a urine cytology, an ultrasound of the urinary tract and a cystoscopy [^3][^11].
Many patients in Delhi, Gurgaon and Noida are picked up during a corporate or pre-insurance health check that reveals red blood cells on a urine dipstick, without visible discolouration. Persistent unexplained microscopic haematuria after the age of forty warrants urology referral [^11].
Irritative lower urinary tract symptoms that do not respond to antibiotics and where the urine culture is negative also deserve attention. Increased urinary frequency, urgency and dysuria (a burning sensation during urination) form the classic presentation of carcinoma in situ, which irritates the bladder lining diffusely. A patient being treated repeatedly for “UTI” with negative cultures should be sent for cystoscopy [^3][^6].
Symptoms of Locally Advanced and Metastatic Bladder Cancer
As bladder cancer grows beyond the bladder wall or spreads to distant sites, the symptom profile shifts. Flank pain on one side suggests a tumour or enlarged pelvic lymph node is obstructing a ureter, leading to hydronephrosis (swelling of the kidney from backed-up urine). This finding often signals at least locally advanced disease [^11].
Suprapubic or pelvic heaviness, a dull persistent ache in the lower abdomen, grows as the tumour enlarges or invades the outer layers of the bladder wall. Unilateral lower-limb swelling can develop when enlarged pelvic lymph nodes compress the iliac veins and cause oedema in one leg, typically signalling node-positive or locally advanced disease.
Bone pain, weight loss and fatigue are late signs that point to metastatic spread. Bone pain localises to the spine, pelvis or ribs. Unexplained weight loss and declining energy often accompany distant disease. A weak or interrupted urinary stream may develop when a tumour near the bladder neck or prostatic urethra obstructs flow and mimics benign prostatic enlargement in older men [^11].
None of these symptoms proves cancer on its own. Infections, stones, prostate enlargement and even vigorous exercise can cause blood in the urine. The purpose of listing them is to ensure that patients who experience these signs, particularly painless visible haematuria, seek a urology evaluation rather than wait [^3][^11].
Causes and Risk Factors for Bladder Cancer in India
Tobacco smoking is the single largest modifiable risk factor for bladder cancer in India and globally. The aromatic amines and polycyclic aromatic hydrocarbons in tobacco smoke are absorbed into the bloodstream, filtered by the kidneys, concentrated in urine and sit in prolonged contact with the urothelium. Both cigarette and bidi smoking carry risk, and the risk is dose-dependent. Data from the ICMR National Cancer Registry Programme and hospital-based series at a tertiary cancer centre and a tertiary cancer centre show that smoking accounts for a large majority of male bladder cancer cases. Quitting reduces risk over time, though it takes many years to approach baseline levels [^10][^12][^13].
Occupational chemical exposure is the second most established risk factor. Workers in dye manufacturing, rubber production, leather tanning, textile finishing, paint production, printing and aluminium smelting face higher bladder cancer rates because of exposure to aromatic amines including benzidine and 2-naphthylamine. India banned benzidine for industrial use, but exposure continues in informal workshops. The ICMR consensus document notes that roughly half of cases in one large Indian series occurred among labourers and industrial workers [^10][^13][^14].
Other risk factors include chronic bladder irritation from long-standing catheterisation, bladder stones or recurrent urinary infections; prior pelvic radiation for cervical, prostate or rectal cancer; long-term cyclophosphamide or ifosfamide exposure without mesna uroprotection; arsenic contamination in drinking water (documented in parts of West Bengal, Bihar, Jharkhand and Assam); aristolochic acid in unregulated herbal preparations; and Lynch syndrome with germline mismatch repair gene mutations [^10][^11][^13].
Age and sex shape the risk profile. Bladder cancer risk rises steeply after age fifty, with most diagnoses after sixty. Indian men are diagnosed roughly four to nine times more often than women, partly explained by higher tobacco use and greater occupational exposure among men [^12][^13].
How Bladder Cancer Is Diagnosed in Delhi, Gurgaon and Noida
The diagnostic pathway moves through urine tests, direct visualisation of the bladder interior, tissue sampling and imaging. Most patients enter this pathway after a urologist sees them for visible blood in the urine or an abnormal finding on ultrasound [^3][^15].
Urine cytology examines a sample under the microscope for shed cancer cells. Cytology is particularly sensitive for high-grade urothelial carcinoma and carcinoma in situ but less reliable for low-grade papillary tumours. Enhanced urine-based assays exist, including fluorescence in situ hybridisation (FISH, marketed as UroVysion) and the nuclear matrix protein 22 (NMP22) test, but cystoscopy remains the definitive step [^3][^15][^16].
Cystoscopy is the backbone of diagnosis. The urologist passes a thin telescope through the urethra into the bladder and inspects the entire lining in a systematic sweep. Any suspicious growth, red patch or irregular area is noted, mapped and biopsied. Standard white-light cystoscopy (WLC) is available at all major NCR centres. Enhanced cystoscopy using photodynamic diagnosis (PDD, also called blue-light cystoscopy) involves instilling a photosensitising agent such as hexaminolevulinate into the bladder before the procedure. Under blue-violet light, cancerous tissue fluoresces bright pink-red, improving detection of flat CIS and small satellite tumours that white light can miss [^5][^15][^16].
Transurethral resection of bladder tumour (TURBT) is both diagnostic and therapeutic. Under anaesthesia, the urologist resects the visible tumour in layers and sends each layer as a separate specimen. The resection must include the underlying muscle so the pathologist can determine whether muscle invasion has occurred. If the initial specimen lacks muscle, or if a high-grade T1 tumour is found, a re-staging TURBT within two to six weeks is recommended [^3][^5][^6][^16].
Imaging for Bladder Cancer: CT Urogram, MRI and VI-RADS
CT urogram is the standard imaging study for evaluating upper urinary tract involvement, lymph node enlargement and distant metastasis. A contrast-enhanced CT of the abdomen and pelvis with delayed images of the kidneys, ureters and bladder replaces the older intravenous pyelogram at most centres in Delhi, Gurgaon and Noida. It shows hydronephrosis, tumour extension beyond the bladder wall and pelvic or retroperitoneal lymphadenopathy [^15][^17].
Multiparametric MRI of the pelvis offers superior soft-tissue contrast and can help distinguish between T2 and T3 disease when CT findings are equivocal. The Vesical Imaging Reporting and Data System (VI-RADS) is a structured scoring system that rates the probability of muscle invasion on a five-point scale. It is increasingly used at tertiary centres to guide the decision between bladder-preserving therapy and radical surgery [^17].
A CT scan of the chest is standard for muscle-invasive disease to rule out pulmonary metastases. A bone scan is ordered when the patient has bone pain, elevated alkaline phosphatase or other clinical suspicion of skeletal metastases. Fluorodeoxyglucose PET-CT is not routinely used for primary bladder cancer because the radiotracer is excreted through the kidneys and concentrates in the bladder, obscuring local tumour detail. It may be considered when conventional imaging is inconclusive about distant spread [^5][^15][^17].
Pathology and TURBT in Bladder Cancer Staging
The TURBT specimen is the single most important piece of information in bladder cancer staging. It provides the histologic type, grade, depth of invasion and presence or absence of lymphovascular invasion, all of which feed into the staging and risk-stratification process [^3][^5][^16].
Resection must be performed in layers so the pathologist can assess each stratum of the bladder wall separately. If the deepest chip does not contain muscularis propria, the pathologist cannot confirm or exclude muscle invasion, and the staging is incomplete. This is why guidelines mandate a re-staging TURBT when muscle is absent from the initial specimen or when a high-grade T1 tumour is diagnosed: up to 40 percent of T1 tumours are upstaged to T2 on re-resection [^5][^6][^16].
Bimanual examination under anaesthesia (EUA) adds clinical staging information. While the patient is anaesthetised for TURBT, the surgeon palpates the bladder between a hand on the abdomen and a finger in the rectum (or vagina). A mobile mass that disappears after resection suggests organ-confined disease. A fixed or thickened area that persists after resection suggests invasion through the bladder wall into surrounding tissue, corresponding to clinical T3 or T4 [^3][^5].
Random biopsies of normal-appearing mucosa in other parts of the bladder and the prostatic urethra may be taken when CIS is suspected. These mapping biopsies help determine whether the field change is widespread and guide decisions about bladder preservation versus cystectomy [^6][^16].
Intravesical Therapy for Non-Muscle-Invasive Bladder Cancer
Intravesical therapy means instilling a drug directly into the bladder through a catheter. It delivers high local concentrations while limiting systemic side effects. Three main categories are used at NCR centres [^3][^5][^6].
Single post-TURBT instillation. Within 24 hours of TURBT for a suspected low-risk Ta tumour, a single dose of mitomycin C (40 mg in 40 mL saline) or gemcitabine (2 g in 100 mL saline) is instilled and held for one to two hours. This single instillation reduces the one-year recurrence rate by roughly 35 to 40 percent compared with TURBT alone [^3][^5][^6].
Intravesical BCG (Bacillus Calmette-Guerin) is a live attenuated strain of Mycobacterium bovis that triggers an immune response within the bladder wall. It remains the most effective intravesical agent for intermediate- and high-risk NMIBC. The standard induction schedule is one instillation per week for six consecutive weeks. Maintenance BCG, typically using the SWOG schedule (three weekly instillations at months 3, 6, 12, 18, 24, 30 and 36), reduces both recurrence and progression. A global BCG shortage that began around 2019 has intermittently affected supply in India, prompting the use of reduced-dose schedules and alternative agents [^3][^5][^6][^10].
Sequential intravesical gemcitabine and docetaxel has emerged as an option for patients who have failed BCG or when BCG is unavailable. Gemcitabine (1 g, dwell time one hour) followed by docetaxel (37.5 mg, dwell time one to two hours) has shown a one-year high-grade recurrence-free survival of approximately 60 to 70 percent in published series [^19][^25].
Radical Cystectomy and Urinary Diversion for Bladder Cancer
Radical cystectomy is the standard surgical treatment for muscle-invasive bladder cancer. In men, the procedure removes the bladder, prostate and seminal vesicles en bloc (radical cystoprostatectomy). In women, the uterus, fallopian tubes, ovaries and a portion of the anterior vaginal wall are typically removed along with the bladder (anterior pelvic exenteration), though organ-sparing modifications are offered at several NCR centres for selected patients. Bilateral pelvic lymph node dissection is performed simultaneously; an extended dissection up to the aortic bifurcation provides better staging and may confer a survival benefit [^5][^10][^18].
Three main urinary diversion options are discussed with the patient before surgery. An ileal conduit is the most commonly performed diversion: a segment of ileum is fashioned into a short tube, the ureters are connected to one end, and the other end is brought out through the abdominal wall as a stoma that drains into an external collection bag. An orthotopic neobladder (such as the Studer or Hautmann ileal neobladder) is created from detubularised ileum shaped into a pouch and connected to the urethra, allowing the patient to void through the normal route with timed voiding and pelvic floor exercises. A continent cutaneous diversion (such as the Indiana pouch) creates an internal reservoir that the patient empties by self-catheterisation through a small abdominal stoma [^5][^10][^27].
Robotic-assisted radical cystectomy with intracorporeal urinary diversion is performed at high-volume centres in Delhi and Gurgaon, offering shorter hospital stays and reduced blood loss in experienced hands. Large comparative studies show that robotic and open radical cystectomy have similar cancer control outcomes. Complication rates at 90 days are broadly comparable when the surgeon has sufficient robotic volume [^27].
Partial cystectomy, removal of only the tumour-bearing portion with adequate margins, is an option for a highly selected minority: typically a solitary muscle-invasive tumour at the dome, no CIS elsewhere, and no prior multifocal disease. Bilateral pelvic lymph node dissection is still performed. Partial cystectomy is feasible in fewer than five percent of MIBC patients [^5][^10].
Trimodal Therapy for Bladder-Preserving Treatment
Trimodal therapy (TMT) offers an alternative to radical cystectomy for patients with muscle-invasive bladder cancer who are medically fit but strongly prefer to keep their bladder, or who are not candidates for cystectomy due to comorbidities. TMT consists of three components delivered in sequence [^5][^10][^30].
First, a maximal TURBT that removes all visible tumour. Second, concurrent radiosensitising chemotherapy, most commonly low-dose cisplatin (typically 35 mg/m2 weekly during radiation or 100 mg/m2 on days 1 and 22) or 5-fluorouracil with mitomycin C. Third, external-beam radiation therapy to the bladder, usually 60 to 66 Gy delivered in daily fractions over six to seven weeks.
Ideal candidates for bladder-preserving TMT have a single T2 tumour, complete visible resection at TURBT, no CIS, no hydronephrosis and adequate bladder capacity. Published long-term series from Massachusetts General Hospital and the BC2001 and BCON UK trials report five-year overall survival rates of 50 to 60 percent for selected patients, comparable to cystectomy series. In the National Capital Region, TMT is offered at radiation oncology departments of leading cancer centres and other centres [^5][^10][^30].
Neoadjuvant and Adjuvant Systemic Therapy for Bladder Cancer
Neoadjuvant cisplatin-based chemotherapy before cystectomy is the standard of care for cT2-T4a N0 M0 bladder cancer. Two regimens have the strongest evidence. Gemcitabine plus cisplatin (GC): gemcitabine 1,000 mg/m2 on days 1 and 8 with cisplatin 70 mg/m2 on day 1, repeated every 21 days for three to four cycles. Dose-dense MVAC: methotrexate 30 mg/m2 day 1, vinblastine 3 mg/m2 day 2, doxorubicin 30 mg/m2 day 2, and cisplatin 70 mg/m2 day 2, with G-CSF support, repeated every 14 days for three to four cycles. The ABC Meta-analysis Collaboration demonstrated a five percent absolute overall survival benefit at five years [^5][^18][^28].
The NIAGARA trial (phase III) tested perioperative durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab versus chemotherapy alone and showed statistically significant improvements in event-free survival and overall survival. The EV-303/KEYNOTE-905 trial evaluated perioperative enfortumab vedotin plus pembrolizumab versus surgery alone in cisplatin-ineligible patients and reported a pathological complete response rate of 57.1 percent versus 8.6 percent, with significant event-free survival and overall survival gains [^22][^29].
Adjuvant nivolumab for patients who underwent radical cystectomy and have high-risk pathological features (ypT2-ypT4a or ypN+ after neoadjuvant chemotherapy, or pT3-pT4a or pN+ without prior neoadjuvant chemotherapy) is supported by CheckMate 274. Nivolumab 240 mg intravenously every two weeks for up to one year nearly doubled median disease-free survival compared with placebo. Five-year follow-up confirmed durable benefit, particularly in PD-L1-positive patients [^20][^21].
First-Line Enfortumab Vedotin Plus Pembrolizumab for Metastatic Bladder Cancer
Enfortumab vedotin is an antibody-drug conjugate targeting Nectin-4, a protein expressed on the surface of most urothelial carcinoma cells. Combined with the PD-1 checkpoint inhibitor pembrolizumab, it forms the preferred first-line regimen for locally advanced unresectable or metastatic urothelial carcinoma regardless of cisplatin eligibility [^22][^23][^24].
The evidence comes from the phase III EV-302/KEYNOTE-A39 trial, which randomised 886 patients to EV plus pembrolizumab or platinum-based chemotherapy. Median overall survival was 31.5 months versus 16.1 months (hazard ratio 0.47). Median progression-free survival was 12.5 months versus 6.3 months. The 2.5-year follow-up update reported median overall survival of 33.8 months versus 15.9 months, confirming durability. Grade 3 or higher adverse events occurred in 55.9 percent of the EV+P group versus 69.5 percent of the chemotherapy group [^22][^23][^24].
The main toxicities of the combination include peripheral neuropathy, skin reactions (rash, pruritus, dry skin) and hyperglycaemia. Patients with pre-existing poorly controlled diabetes or peripheral neuropathy need closer monitoring. In India, enfortumab vedotin availability is expanding but cost remains a barrier; patient assistance programmes and clinical trials may improve access for NCR patients [^22][^24].
Second-Line and FGFR-Targeted Therapy for Urothelial Carcinoma
After progression on first-line treatment, several options exist for metastatic urothelial carcinoma, guided by prior therapy and tumour molecular profile [^5][^22][^23].
Enfortumab vedotin monotherapy (1.25 mg/kg intravenously on days 1, 8 and 15 of a 28-day cycle) is the standard second-line option if the drug was not used first-line, based on the EV-301 trial. Erdafitinib (Balversa), an oral fibroblast growth factor receptor inhibitor, is indicated for patients whose tumours harbour susceptible FGFR3 or FGFR2 genetic alterations (point mutations or fusions). The THOR trial showed superior overall survival over chemotherapy in the FGFR-altered population, making molecular testing for FGFR alterations a standard part of the metastatic workup [^5][^22][^23].
Sacituzumab govitecan (Trodelvy), an antibody-drug conjugate targeting Trop-2, has shown activity in platinum- and checkpoint-inhibitor-refractory urothelial cancer in the TROPiCS-04 trial. Taxane-based chemotherapy (docetaxel or paclitaxel) remains a fallback option when targeted agents are unavailable or when performance status allows one more line of treatment. Clinical trial enrolment should be discussed at every progression point [^22][^23].
Cost of Bladder Cancer Treatment in Delhi, Gurgaon and Noida
Treatment costs for bladder cancer depend on the stage at diagnosis, the procedures required, the hospital category (government, private or trust) and whether the patient holds a subsidised scheme card such as CGHS, ECHS or Ayushman Bharat PMJAY. The figures below are approximate ranges gathered from hospital rate cards, medical tourism aggregators and published Indian oncology cost analyses as of early 2026 [^32][^33][^34].
A standard staging workup (cystoscopy with biopsy, urine cytology, contrast-enhanced CT abdomen and pelvis, blood work) typically costs 15,000 to 40,000 rupees at a private NCR hospital. At a tertiary cancer centre Delhi or a government hospital, the same investigations may cost 3,000 to 8,000 rupees. A PET-CT scan adds 12,000 to 25,000 rupees at most private centres [^32][^35].
TURBT costs 40,000 to 1,50,000 rupees at a private hospital depending on anaesthesia type, tumour count and hospital stay. Government hospital charges are 10,000 to 30,000 rupees. A six-week BCG induction course followed by maintenance for one to three years can total 50,000 to 2,00,000 rupees at a private centre. Each BCG instillation costs roughly 3,000 to 8,000 rupees [^32][^33][^36][^37].
Open radical cystectomy with ileal conduit costs 3,00,000 to 6,00,000 rupees at a private hospital. Robotic-assisted cystectomy costs 5,00,000 to 9,00,000 rupees. An orthotopic neobladder adds 50,000 to 1,50,000 rupees over an ileal conduit. At a tertiary cancer centre Delhi, the out-of-pocket cost in a general ward may be 50,000 to 1,50,000 rupees [^32][^33][^36][^38].
Gemcitabine plus cisplatin chemotherapy costs approximately 15,000 to 35,000 rupees per cycle at a private day-care unit, so a four-cycle neoadjuvant course runs 60,000 to 1,40,000 rupees. Pembrolizumab is priced at roughly 80,000 to 1,10,000 rupees per dose (200 mg). Enfortumab vedotin is not yet widely available through domestic retail pharmacies as of early 2026, with access mainly through compassionate use or clinical trials. Erdafitinib may cost 2,00,000 to 3,50,000 rupees per month when sourced internationally [^33][^34][^39][^40][^41].
IMRT or VMAT-based radiation for trimodal therapy costs 1,50,000 to 3,50,000 rupees for the full course at a private centre. Palliative radiation (five to ten fractions) costs 30,000 to 80,000 rupees. Government hospitals with linear accelerators offer subsidised or no-cost radiation for eligible patients [^33][^35][^42].
Ayushman Bharat PMJAY covers eligible families for up to five lakh rupees per year, and cystectomy and chemotherapy fall within the procedure list. CGHS covers central government employees and pensioners at CGHS package rates, typically 30 to 50 percent below rack rates. Delhi Arogya Kosh can bridge gaps for patients who do not qualify for PMJAY. Most private hospitals also maintain patient welfare or charitable trust funds [^32][^35].
Bladder Cancer Patient and Family FAQs
My cystoscopy report says pTa low grade. Does that mean I still have cancer?
Yes, pTa low grade is a real bladder cancer, but it sits on the surface of the bladder lining and has not grown into deeper layers. The risk of it spreading outside the bladder is very low. The main concern is recurrence inside the bladder. Your urologist will schedule surveillance cystoscopies, initially every three months, to catch any new growths early. Most patients with pTa low-grade disease live a normal lifespan, though they may need repeat TURBT procedures if tumours recur [^3][^4][^6].
What is the difference between clinical stage and pathological stage?
Clinical stage is assigned before major surgery, using cystoscopy, biopsy and imaging (CT or MRI). Pathological stage is assigned after the surgeon removes the bladder and the pathologist examines the tissue under a microscope. Pathological staging is more accurate because it reveals exactly how deep the tumour invaded and whether lymph nodes contain cancer cells. It is common for the pathological stage to differ from the clinical stage [^1][^2][^5].
I have been told I need a radical cystectomy. Will I need a bag for life?
Not necessarily. If your surgeon determines that your urethra is free of cancer and your overall health allows a longer operation, you may be a candidate for an orthotopic neobladder, a new bladder constructed from a segment of your intestine and connected to your urethra. With a neobladder you urinate through the normal route, though the sensation differs and you will need to learn timed voiding and pelvic floor exercises. The alternative is an ileal conduit, where urine drains continuously into an external pouch attached to a stoma on your abdomen. Both options are routinely performed at major hospitals in Delhi and Gurgaon. Your surgeon will explain which diversion suits your anatomy and tumour location [^5][^27][^38].
Is robotic cystectomy safer than open surgery?
Large comparative studies show that robotic and open radical cystectomy have similar cancer control outcomes. Robotic surgery is associated with less blood loss during the operation and a somewhat shorter hospital stay. Complication rates at 90 days are broadly comparable when the surgeon has sufficient experience with the robotic platform. The choice should be guided by your surgeon’s expertise rather than a general assumption that robotic is automatically superior [^27][^36].
Can bladder cancer come back after removing the entire bladder?
Yes. Even after radical cystectomy, cancer can recur in the pelvic region, in distant organs, or in the upper urinary tract (the ureters or kidneys share the same urothelial lining). The risk of recurrence depends on the pathological stage and whether lymph nodes were positive. Neoadjuvant chemotherapy before surgery and adjuvant nivolumab after surgery are both designed to reduce this risk. Lifelong surveillance with imaging and blood tests is standard [^5][^20][^21][^28].
How long does chemotherapy last for bladder cancer?
For neoadjuvant chemotherapy before cystectomy, the usual course is three to four cycles of gemcitabine plus cisplatin given every 21 days, so roughly nine to twelve weeks. For metastatic disease treated with first-line chemotherapy followed by avelumab maintenance, the chemotherapy portion is four to six cycles (twelve to eighteen weeks) and maintenance continues until progression or unacceptable side effects. If you receive enfortumab vedotin plus pembrolizumab as first-line treatment, cycles are 21 days long and treatment continues as long as it is working and tolerable [^5][^22][^23][^31].
I have T1 high-grade bladder cancer and my doctor recommended BCG. What happens if BCG fails?
If your tumour recurs or persists after an adequate course of BCG (typically at least one induction course and one or more maintenance courses), your disease is classified as BCG-unresponsive. The standard recommendation at that point is radical cystectomy because the risk of progression to muscle-invasive disease is high. For patients who are unfit for or unwilling to undergo cystectomy, bladder-sparing options include pembrolizumab (KEYNOTE-057 trial), nadofaragene firadenovec gene therapy (Adstiladrin), and sequential intravesical gemcitabine plus docetaxel. Your oncologist at centres in Delhi, Gurgaon or Noida can discuss which option fits your situation and whether a clinical trial is available [^5][^6][^19][^25][^26].
What questions should I ask at my tumour board meeting?
Consider asking: What is my exact TNM stage and grade? Is my tumour non-muscle-invasive or muscle-invasive? Do I need neoadjuvant chemotherapy before surgery? Am I a candidate for bladder preservation with trimodal therapy? If I need a cystectomy, which urinary diversion do you recommend for me and why? Are there any clinical trials open at your centre for my stage? What is the expected timeline from first treatment to recovery? [^5][^6]
Are treatment costs covered by Ayushman Bharat or CGHS?
Ayushman Bharat PMJAY covers eligible families for up to five lakh rupees per year for secondary and tertiary hospital care at empanelled hospitals, and bladder cancer surgery and chemotherapy are included in the procedure list. CGHS covers central government employees and pensioners at empanelled hospitals, reimbursing at CGHS package rates. The extent of out-of-pocket expense depends on the hospital category and room selection. If your estimated treatment cost exceeds the scheme limit, the hospital social worker can help you apply for bridge funding through state cancer funds or charitable trusts [^32][^35].
[^1]: Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual, 8th edition. Springer, 2017. Chapter on urinary bladder. [^2]: Shariat SF, Palapattu GS, Karakiewicz PI, et al. Staging of bladder cancer. Pubmed 30565300. [^3]: NIH/NCI PDQ Bladder Cancer Treatment (Health Professional Version). cancer.gov. [^4]: Lenis AT, Lec PM, Chamie K. Non-muscle-invasive bladder cancer: overview and contemporary treatment field. PMC 7393683. [^5]: NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. nccn.org. [^6]: EAU Guidelines on Non-Muscle-Invasive Bladder Cancer and Muscle-Invasive and Metastatic Bladder Cancer. [^7]: Comperat E, et al. News in the classification of WHO 2022 bladder tumors. PMC 10342216. [^8]: Lopez-Beltran A, et al. Recent advances in the classification of bladder cancer: updates from the 5th edition of the WHO classification. PMC 11181758. [^9]: Humphrey PA, et al. Invasive urothelial carcinoma: subtypes and divergent differentiation. NCBI Bookshelf NBK585978. [^10]: ICMR Consensus Document for Management of Urinary Bladder Cancer. icmr.gov.in. [^11]: NCI PDQ Bladder Cancer Treatment (Patient Version) and SEER Cancer Stat Facts: Bladder Cancer. cancer.gov and seer.cancer.gov. [^12]: ICMR National Cancer Registry Programme. Cancer incidence estimates for 2022 and projection for 2025. PMC 10231735. [^13]: Dikshit R, et al. Tobacco-related cancers in India: a review of incidence reported from population-based cancer registries. PMC 5027787. [^14]: Murthy NS, Agarwal UK, Chaudhry K, et al. Genitourinary cancers: summary of Indian data. PMC 4991131. [^15]: NCI PDQ Bladder Cancer Diagnosis page. cancer.gov. [^16]: Daneshmand S, et al. Optimizing cystoscopy and TURBT: enhanced imaging and artificial intelligence. PMC 11939114. [^17]: Woo S, et al. The role of imaging in bladder cancer diagnosis and staging. PMC 7555625. [^18]: AJCC Cancer Staging Manual, 8th edition. Stage group definitions for bladder. [^19]: Boorjian SA, et al. Nadofaragene firadenovec gene therapy for BCG-unresponsive NMIBC. FDA label and NCT02773849. [^20]: Bajorin DF, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. NEJM 2021. CheckMate 274. PubMed 34077643. [^21]: Galsky MD, et al. Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274. PubMed 39393026. [^22]: Powles T, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. NEJM 2024. EV-302/KEYNOTE-A39. PubMed 38446675. [^23]: NCCN Guidelines: Bladder Cancer, version 2.2025. [^24]: Powles T, et al. EV-302 2.5-year median follow-up update. PubMed 40460988. [^25]: Steinberg RL, et al. Sequential intravesical gemcitabine/docetaxel for recurrent high-risk NMIBC following BCG therapy. PubMed 37690933. [^26]: de Wit R, et al. Pembrolizumab for BCG-unresponsive NMIBC: KEYNOTE-057 cohort A. Lancet Oncol 2021. [^27]: NCBI Bookshelf NBK604466. Robotic radical cystectomy. StatPearls. [^28]: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer. Eur Urol 2005. [^29]: Galsky MD, et al. Perioperative enfortumab vedotin and pembrolizumab: EV-303/KEYNOTE-905. PubMed 41707170. [^30]: Efstathiou JA, et al. Long-term outcomes of combined-modality therapy for invasive bladder cancer. MGH series. BC2001 and BCON UK trials. [^31]: Powles T, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. JAVELIN Bladder 100. NEJM 2020. [^32]: Indicure Health Tours. Bladder Cancer Treatment Cost in India. indicure.com. [^33]: CancerRounds. Bladder Cancer Treatment Cost in India. cancerrounds.com. [^34]: Dr Ankur Bahl. Bladder Cancer Treatment in India. drankurbahl.com. [^35]: Delhi Government e-Health Services. a tertiary cancer centre rates for treatment procedures. dgehs.delhi.gov.in. [^36]: Medfin. Cystectomy for Bladder Cancer Cost Estimate. medfin.in. [^37]: Sriram LM, et al. Comparing adverse effects and cost of hyperthermic intravesical chemotherapy with Mitomycin-C and intravesical BCG. PMC 8525474. [^38]: a leading cancer centre. Robotic Cystectomy. maxhealthcare.in. [^39]: Annals of Oncology. Cost comparison of originator and generic chemotherapy drugs in India. annalsofoncology.org. [^40]: Wen T, et al. Cost-effectiveness of first-line enfortumab vedotin plus pembrolizumab. PMC 11416998. [^41]: Oncology Nursing News. Newer Urothelial Cancer Drugs Are Effective But Pricey. oncnursingnews.com. [^42]: HexaHealth. Chemotherapy Cost in Delhi. hexahealth.com.
Overview
Treatment Options